TBRG vs. COYA, INCR, CRDL, BCAB, PDSB, KNTE, RNAC, RPTX, VXRT, and OMGA
Should you be buying TruBridge stock or one of its competitors? The main competitors of TruBridge include Coya Therapeutics (COYA), InterCure (INCR), Cardiol Therapeutics (CRDL), BioAtla (BCAB), PDS Biotechnology (PDSB), Kinnate Biopharma (KNTE), Cartesian Therapeutics (RNAC), Repare Therapeutics (RPTX), Vaxart (VXRT), and Omega Therapeutics (OMGA). These companies are all part of the "medical" sector.
TruBridge (NASDAQ:TBRG) and Coya Therapeutics (NASDAQ:COYA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.
Coya Therapeutics has a net margin of 0.00% compared to TruBridge's net margin of -13.49%. TruBridge's return on equity of 10.33% beat Coya Therapeutics' return on equity.
88.6% of TruBridge shares are held by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are held by institutional investors. 3.6% of TruBridge shares are held by insiders. Comparatively, 12.0% of Coya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Coya Therapeutics received 4 more outperform votes than TruBridge when rated by MarketBeat users. However, 100.00% of users gave TruBridge an outperform vote while only 87.50% of users gave Coya Therapeutics an outperform vote.
Coya Therapeutics has lower revenue, but higher earnings than TruBridge. Coya Therapeutics is trading at a lower price-to-earnings ratio than TruBridge, indicating that it is currently the more affordable of the two stocks.
TruBridge has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, Coya Therapeutics has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500.
In the previous week, TruBridge had 8 more articles in the media than Coya Therapeutics. MarketBeat recorded 8 mentions for TruBridge and 0 mentions for Coya Therapeutics. Coya Therapeutics' average media sentiment score of 0.59 beat TruBridge's score of 0.00 indicating that Coya Therapeutics is being referred to more favorably in the news media.
TruBridge presently has a consensus price target of $18.50, indicating a potential upside of 123.70%. Coya Therapeutics has a consensus price target of $14.00, indicating a potential upside of 74.35%. Given TruBridge's higher probable upside, equities research analysts plainly believe TruBridge is more favorable than Coya Therapeutics.
Summary
TruBridge and Coya Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get TruBridge News Delivered to You Automatically
Sign up to receive the latest news and ratings for TBRG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TBRG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TruBridge Competitors List
Related Companies and Tools
